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subset of patients with PAH may benefit most while minimizing overall risk and resource utilization.4−6 It will be
crucially important to identify those patients with PAH that
have a reasonable perspective for recovery. One way to
assess this is to determine which patients with PAH have
low-to-intermediate calculated 1-year mortality (such as
using the Registry to Evaluate Early and Long-Term PAH
Disease Management 2.0 score (≤8 is favorable). Perhaps,
this small subset of patients with PAH should continue to
be considered for mechanical support and/or transplant,
irrespective of PAH itself, however noting that this will
require ongoing input and assessment from the advanced
transplant team, weighing risks/benefits and considering
similar parameters in other individuals concurrently listed,
to identify those patients with the best chance for a full
recovery and least resource utilization (utility).
We must also consider the effects of COVID-19 on the
patient with PAH more specifically. It is not entirely clear
whether patients with underlying pulmonary disease and
PAH do worse with COVID-19.7 Therefore, it is not likely
fair (justice) to impart resource restriction to the patient
with PAH listed for transplant during the pandemic on the
basis of disease process alone. Reflecting further on PAH,
one must consider the unique pathophysiologic consequences inflicted upon the cardiovascular and pulmonary systems in those infected with COVID-19. Indeed, both the
disease itself and subsequent treatment (ventilation and positive end-expiratory pressure) have profound adverse
effects on the right ventricle, which in many cases is
already adversely remodeled in PAH. Thus, it would be
anticipated that patients with PAH with COVID-19 would
not fare well and that resource allocation might be best utilized for others. Conversely, given that significant endothelial dysfunction and vascular complications are implicated
in COVID-19, theoretically, PAH-specific medications may
be beneficial as they target endothelial function and offload the right ventricle.4,5 In addition, several PAH-specific
therapies may also impart direct anti-Coronaviridae viral
effects.8,9
In summary, operational ethical principles applied to the
overarching cardiovascular and pulmonary transplant
groups should equally extend to those with an underlying
diagnosis of pulmonary vascular disease. It is important to
maintain accessibility to invasive hemodynamic testing in
those patients with new and/or suspected worsening of
PAH despite the stage of the current pandemic. Finally,
advanced resources such as mechanical circulatory support
and organ transplant may be considered in a small subset of
patients with PAH identified as having a reasonable perspective of recovery and if overall vetted risk among other
recipients remains relatively low.
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There is increasing evidence that severe acute respiratory syndrome coronavirus (CoV) 2 (SARS-CoV-2)
impacts the neurologic system.1−3 However, how the
immunosuppressed state modifies neurologic involvement
and clinical course remains uncertain.4 We describe a
patient with heart transplant who developed prolonged
symptoms of encephalopathy late in CoV disease 2019
(COVID-19) illness.
A 67-year-old man was admitted with fever, cough,
nasal congestion, sore throat, and diarrhea 20 months after
an uneventful heart transplantation. He was not hypoxic.
Chest computed tomography (CT) showed bilateral multifocal peripheral ground-glass opacities (GGOs). White
blood cell count was 4,720/ml with lymphocyte count of
1,040/ml. Blood cultures and cytomegalovirus polymerase
chain reaction (PCR) were unremarkable. C-reactive protein (CRP) was 0.55 mg/dl. Nasopharyngeal PCR for
SARS-CoV-2 was positive, consistent with COVID-19 illness. Immunosuppression included 500 mg mycophenolate
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Figure 1

Fever and CRP Trend Following Admission. CRP, C-reactive protein.

twice daily (BID) and tacrolimus with trough level of
7.6 ng/ml at admission. Mycophenolate was discontinued.
Tacrolimus was maintained for a goal level of 7‒10 ng/ml.
He continued to have intermittent fevers (Figure 1) but was
never hypoxic. Chest CT on Day 6 showed worsening
GGOs. Hydroxychloroquine was started on Day 7 (400 mg
BID on the first day, then 200 mg BID for 4 days). He was
discharged on Day 9.
He was readmitted after 2 days with confusion, anorexia,
and emesis. He was alert, oriented only to person, and
febrile. He had no previous history of delirium or encephalopathy and was on stable home dose of venlafaxine for the
treatment of a history of depression. Examination was notable for postural and action tremor, without focal neurologic
deficits. CRP was increased to 10.7 mg/dl with a mild elevation in aspartate transaminase and alanine transaminase
to a maximum of 74 U/liter and 79 U/liter, respectively.
Serum ammonia and thyroid-stimulating hormone were
normal. Serum sodium was decreased to 133 milliequivalents/liter (normal range 135−145 milliequivalents/liter)
but returned to normal by Day 2 of readmission. Blood urea
nitrogen and serum creatinine were 42 mg/dl and
1.73 mg/dl, respectively, unchanged from baseline. Trough
tacrolimus level at readmission was 11.5 ng/ml and averaged to 10 § 1.2 ng/ml during the admission. Hydroxychloroquine was discontinued.
CT scan of the head was unremarkable. Chest CT showed
minimal progression of GGOs. Brain magnetic resonance
imaging showed mild scattered foci of peri-ventricle deep
and sub-cortical white matter ischemia. There was no evidence of encephalitis, posterior reversible encephalopathy, or
leukoencephalopathy. Repeat magnetic resonance imaging
after 1 week was unchanged. Electroencephalogram showed
mild non-specific diffuse multifocal cerebral dysfunction
with no seizure seen. Lumbar puncture showed 1 lymphocyte, normal protein, and glucose. Cerebrospinal fluid (CSF)
was negative for herpes simplex PCR and Cryptococcus antigen. PCR of CSF, not validated for the detection of SARS-

CoV-2, was negative. By Day 16, CRP began to decline.
Mental status slowly improved, and he was discharged
13 days after readmission. Executive function and memory
remained poor but gradually returned to normal approximately 45 days after the onset of the encephalopathy.
Whereas we were unable to demonstrate the presence of
SARS-CoV-2 virus in the CSF of our patient, no alternative
diagnosis for his encephalopathy was found. Sepsis was
unlikely to be an explanation because symptoms started
after clinical stabilization and he had limited signs or symptoms of organ dysfunction. Hydroxychloroquine has been
associated with neurologic changes, but symptoms persisted
for more than 2 weeks after discontinuation.5 The onset of
encephalopathy coincided with increased markers of
inflammation, most notably CRP. The impact of immunosuppression in patients with COVID-19 remains uncertain,
and the severity of illness in case reports has been varied.6,7
It is possible that immunosuppression may attenuate the
severity of disease by limiting the extent of cytokine
release, which may be the primary mediator of injury8;
however, a recent report suggests poor outcomes in hospitalized patients with solid organ transplant.9 The optimal
degree of immunosuppression in patients with heart transplant with COVID-19 remains uncertain.
COVID-19 has been associated with acute hemorrhagic
necrotizing and hypoxic encephalopathy, encephalitis,
delirium, and anosmia.1,10−12 Other b-CoVs such as severe
acute respiratory syndrome-CoV-1 and Middle East respiratory syndrome-CoV have been shown to be neurotropic and
manifest with delirium.1 The angiotensin-converting
enzyme 2 receptor (the primary source of cell entry of the
virus) is expressed in both neurons and glia and could serve
as a mechanism of direct viral entry into the nervous system. Alternatively, the inflammatory state itself may give
rise to encephalopathy,13 and patients with acute respiratory
distress syndrome have been shown to have a high rate of
persistent dysexecutive syndrome similar to that of our
patient3; however, our patient was never hypoxic or
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severely ill before the onset of symptoms, and symptoms
persisted for many days after normalization of markers of
inflammation. Given the novel presentations of COVID-19,
we believe it is important for transplant centers to consider
the potential for delayed neurologic manifestations.
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A 56-year-old African American male with ischemic cardiomyopathy and chronic kidney disease who underwent heart
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transplantation over 1 year before presentation was admitted to
our institution with dry cough, myalgias, and diarrhea concerning for coronavirus disease 2019 (COVID-19) infection. Nasal
swab polymerase chain reaction assay was positive for the
severe acute respiratory syndrome−coronavirus-2 (SARSCoV-2) virus. Initial labs revealed acute kidney injury (creatinine, 1.86 mg/dl). Initial ferritin and IL-6 levels were within
reference range. D-dimer was elevated at 306 ng/ml and
C-reactive protein was elevated at 20.5 mg/liter. Treatment
with hydroxychloroquine and nitazoxanide was initiated. Azithromycin was deferred because of a prolonged corrected QT
of 517 ms. Immunosuppression with tacrolimus was resumed
because of multiple episodes of allograft rejection in the past;
however, mycophenolate and prednisone were stopped. Baseline urine studies had revealed mild nephrotic range proteinuria
(1,973 mg/dl). Over the course of 7 days, his renal dysfunction
rapidly progressed (creatinine peak, 7.78 mg/dl) with marked
elevation in urine protein/creatinine ratio to 7,354 mg/dl.
Inflammatory markers continued to rise (ferritin 637 ng/ml,
IL-6 11 pg/ml, C-reactive protein 61.1 mg/liter, and D-dimer
1,562 ng/ml). Percutaneous needle core kidney biopsy showed
acute tubular injury as well as collapsed capillary tufts with
overlying visceral epithelial cell hyperplasia and protein droplets within Bowman’s space, diagnostic of collapsing glomerulopathy (Figure 1). Electron microscopy revealed coronavirus
particles within the tubular epithelial cells (Figure 2). There
was no evidence of immune complex−mediated or monoclonal-associated disease. Anti-neutrophil cytoplasmic
antibodies, anti−double stranded DNA antibodies, HIV,
and hepatitis serologies were negative. Chest radiography
showed progressive patchy bilateral infiltrates consistent
with atypical pneumonia; however, the patient remained
afebrile with adequate oxygen saturation on room air and
did not require respiratory support. His inflammatory
markers subsequently downtrended, as his renal function
improved with supportive care. He did not require dialysis
and was eventually discharged home.
Collapsing glomerulopathy has a known association to
viral infections, including the first SARS-CoV from the
outbreak in 2002.1 To our knowledge, this is the first
case of collapsing glomerulopathy associated with
COVID-19 infection reported in a heart transplant recipient. Rare reports of similar cases in non-transplant
patients have recently emerged in the literature.2,3 One
case involved a 44-year-old African American female
who was homozygous for the G1 risk allele in the
APOL1 gene (a known risk factor for collapsing glomerulopathy).2 In that report, SARS-CoV-2 RNA was
detected in the biopsy specimen, but whether the patient’s
glomerulopathy was triggered by the virus directly or the
resulting cytokine storm is unclear. Our patient had baseline proteinuria before transplantation and feasibly could
have had an undiagnosed focal segmental glomerulosclerosis before SARS-CoV-2 infection; however, the rapidly
progressive nature of his renal dysfunction and subsequent improvement following resolution of his illness
suggests an association.
The incidence of acute kidney injury (AKI) as a complication of COVID-19 has been variably reported. A case

